{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 41,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The diagram illustrates a standard 3+3 or similar dose escalation design leading to an MTD and subsequent safety expansion.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/33",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.26,
        "x": 0.705,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Safety Expansion: EGFR amp mandatory, Evaluate safety, tolerability, PK/PD, and preliminary efficacy, Determine RP2D",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2427facc-b62d-4438-a493-1a38a6c50f6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.957,
        "x": 0.043,
        "y": 0.225
      },
      "kind": "diagram",
      "text": "Dose escalation steps from 20mg to 320mg, identifying MTD-1 (160mg) and MTD (240mg) leading to safety expansion.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2419f8c8-c69f-4d11-b67f-0c9ffd8579fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.61,
        "x": 0.026,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "Clinicaltrials.gov: NCT05222802. Note: ERAS-801 dosed QD. MTD: maximum tolerated dose; MTD-1 (aka, MTD-minus-1): one dose level below MTD; QD: once daily; amp: amplified; RP2D: recommended Phase 2 dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b551eb89-47ab-4f7d-9594-7a87ee8798e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.358,
        "x": 0.026,
        "y": 0.048
      },
      "kind": "title",
      "text": "THUNDERBBOLT-1: Dose escalation cohorts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "261ece6e-f228-46dc-bc3f-09ff8dc63658",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "76ec06db-2cda-409d-968d-fc917e7aec98",
      "evidence": "Visual representation of dose escalation cohorts and safety expansion",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 38,
      "from": 31,
      "beatId": "655f0f34-999c-4f6f-9941-38fe6e021aa5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "Estimating the market potential of Erasca's treatments",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}